18F-FDG PET/CT Evaluation of Ceritinib Therapy in Metastatic ALK-Positive Non–small Cell Lung Cancer. (November 2016)

• Record Type: Journal Article
• Authors: Dejust, Sebastien; Morland, David; Fabre, Guillaume; Prevost, Alain; Papathanassiou, Dimitri
• Is Part Of: Clinical nuclear medicine. Volume 41:Number 11(2016)
• Publication Date: 2016-11
• Subjects: NSCLC -- 18F-FDG -- PET/CT; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000001361
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: Anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancers (NSCLC) account for 3% to 7% of all NSCLC and require a standard treatment by crizotinib. However, crizotinib resistance is frequent within the first 12 months of treatment. Ceritinib is a novel tyrosine kinase inhibitor of ALK recently introduced in France for metastatic or locally advanced crizotinib-resistant ALK NSCLC. We report the first use of ceritinib in our institution with a spectacular tumoral response after only 3 months of treatment. This case demonstrates the major role of 18 F-FDG PET/CT for monitoring the effectiveness of this new treatment.